These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 37560385)
1. Systematic analysis of the prognosis and immune infiltration of E2Fs in thyroid carcinoma. Fu X; Zhou X; Ji F; He Q; Qiu X Front Genet; 2023; 14():1215984. PubMed ID: 37560385 [No Abstract] [Full Text] [Related]
2. Identification of disulfidptosis-associated genes and characterization of immune cell infiltration in thyroid carcinoma. Song S; Zhou J; Zhang L; Sun Y; Zhang Q; Tan Y; Zhou X; Yu J Aging (Albany NY); 2024 Jun; 16(11):9753-9783. PubMed ID: 38836761 [TBL] [Abstract][Full Text] [Related]
3. HSPA5 is a prognostic biomarker correlated with immune infiltrates in thyroid carcinoma. Dong W; Du D; Huang H Endokrynol Pol; 2022; 73(4):680-689. PubMed ID: 36059163 [TBL] [Abstract][Full Text] [Related]
4. Prognostic Values of E2F1/2 Transcriptional Expressions in Chromophobe Renal Cell Carcinoma Patients: Evidence from Bioinformatics Analysis. Hu D; Meng N; Lou X; Li Z; Teng Y; Tu B; Zou Y; Wang F Int J Gen Med; 2021; 14():3593-3609. PubMed ID: 34295182 [TBL] [Abstract][Full Text] [Related]
5. Bioinformatics analysis for the identification of Sprouty-related EVH1 domain-containing protein 3 expression and its clinical significance in thyroid carcinoma. Zhang X; Meng X; Wang P; Luan C; Wang H Sci Rep; 2024 Feb; 14(1):4549. PubMed ID: 38402263 [TBL] [Abstract][Full Text] [Related]
6. Key molecules associated with thyroid carcinoma prognosis: A study based on transcriptome sequencing and GEO datasets. Bai M; Ke S; Yu H; Xu Y; Yu Y; Lu S; Wang C; Huang J; Ma Y; Dai W; Wu Y Front Immunol; 2022; 13():964891. PubMed ID: 36059514 [TBL] [Abstract][Full Text] [Related]
7. The Prognostic Value of PERK in Cancer and Its Relationship With Immune Cell Infiltration. Wang P; Han L; Yu M; Cao Z; Li X; Shao Y; Zhu G Front Mol Biosci; 2021; 8():648752. PubMed ID: 33937330 [No Abstract] [Full Text] [Related]
8. Identification of the Expression and Clinical Significance of E2F Family in Clear Cell Renal Cell Carcinoma. Chen R; Zhang Z; Hu B; Jiang M; Zheng P; Deng W; Fu B; Sun T Int J Gen Med; 2022; 15():1193-1212. PubMed ID: 35153510 [TBL] [Abstract][Full Text] [Related]
9. Comprehensive Analysis of the Expression and Prognosis for E2Fs in Human Clear Cell Renal Cell Carcinoma. Zhang C; Cui Y; Wang G; Zhao W; Zhao H; Huang X; Zhang M; Li W J Healthc Eng; 2021; 2021():5790416. PubMed ID: 34531966 [TBL] [Abstract][Full Text] [Related]
10. Construction of a ferroptosis-related five-lncRNA signature for predicting prognosis and immune response in thyroid carcinoma. Qin Y; Zhang D; Zhang H; Hou L; Wang Z; Yang L; Zhang M; Zhao G; Yao Q; Ling R; Zhang J Cancer Cell Int; 2022 Sep; 22(1):296. PubMed ID: 36175889 [TBL] [Abstract][Full Text] [Related]
11. LncRNA H19 is a potential biomarker and correlated with immune infiltration in thyroid carcinoma. Sahin Y Clin Exp Med; 2023 Jul; 23(3):841-851. PubMed ID: 35810257 [TBL] [Abstract][Full Text] [Related]
12. Comprehensive Analysis of Prognostic and Immune Infiltrates for E2F Transcription Factors in Human Pancreatic Adenocarcinoma. Liu XS; Gao Y; Liu C; Chen XQ; Zhou LM; Yang JW; Kui XY; Pei ZJ Front Oncol; 2020; 10():606735. PubMed ID: 33604289 [TBL] [Abstract][Full Text] [Related]
13. Identification of ferroptosis genes in immune infiltration and prognosis in thyroid papillary carcinoma using network analysis. Lin R; Fogarty CE; Ma B; Li H; Ni G; Liu X; Yuan J; Wang T BMC Genomics; 2021 Jul; 22(1):576. PubMed ID: 34315405 [TBL] [Abstract][Full Text] [Related]
14. Systematic Analysis of E2F Expression and Its Relation in Colorectal Cancer Prognosis. Xu Z; Qu H; Ren Y; Gong Z; Ri HJ; Zhang F; Shao S; Chen X; Chen X Int J Gen Med; 2022; 15():4849-4870. PubMed ID: 35585998 [TBL] [Abstract][Full Text] [Related]
15. FN1, a reliable prognostic biomarker for thyroid cancer, is associated with tumor immunity and an unfavorable prognosis. Pan H; Luo Z; Lin F; Zhang J; Xiong T; Hong Y; Sun B; Yang Y Oncol Lett; 2024 Nov; 28(5):510. PubMed ID: 39268167 [TBL] [Abstract][Full Text] [Related]
16. Increased FGF2 expression promotes immune cell infiltration and correlates with an unfavorable prognosis in thyroid cancer. Chen H; Du X Heliyon; 2024 Jun; 10(11):e32272. PubMed ID: 38873667 [TBL] [Abstract][Full Text] [Related]
17. Thyroid cancer prognostic biomarker ARL4A and its relationship with immune infiltration. Han X; Liao J; Zhou Y; Hu X; Wu H Int J Clin Exp Pathol; 2024; 17(4):108-120. PubMed ID: 38716351 [TBL] [Abstract][Full Text] [Related]
18. Comprehensive analysis of BTNL9 as a prognostic biomarker correlated with immune infiltrations in thyroid cancer. Zhang L; Yu S; Hong S; Xiao X; Liao Z; Li Y; Xiao H BMC Med Genomics; 2023 Oct; 16(1):234. PubMed ID: 37798795 [TBL] [Abstract][Full Text] [Related]
19. Comprehensive Pan-Cancer Analysis and the Regulatory Mechanism of ASF1B, a Gene Associated With Thyroid Cancer Prognosis in the Tumor Micro-Environment. Ma J; Han W; Lu K Front Oncol; 2021; 11():711756. PubMed ID: 34490109 [TBL] [Abstract][Full Text] [Related]
20. Elevated PDE4C level serves as a candidate diagnostic biomarker and correlates with poor survival in thyroid carcinoma. Wang Y; Zhang Y; Li Y; Huang J Sci Rep; 2024 Mar; 14(1):6813. PubMed ID: 38514754 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]